Astrana Health, Inc. (NASDAQ:ASTH) Receives $65.17 Consensus Target Price from Brokerages

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $65.17.

Several analysts have recently commented on the company. Macquarie raised Astrana Health to a “hold” rating in a report on Monday. BTIG Research upped their target price on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. TD Cowen started coverage on shares of Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 price target for the company. Robert W. Baird raised their price target on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, KeyCorp began coverage on shares of Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating for the company.

Astrana Health Trading Up 0.1 %

ASTH opened at $35.09 on Tuesday. The business has a fifty day moving average price of $48.11 and a 200 day moving average price of $47.99. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health has a 12 month low of $34.11 and a 12 month high of $63.20. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 1.80 and a beta of 1.13.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the previous year, the company earned $0.47 EPS. Sell-side analysts expect that Astrana Health will post 1.16 earnings per share for the current fiscal year.

Institutional Trading of Astrana Health

A number of hedge funds and other institutional investors have recently modified their holdings of ASTH. Central Pacific Bank Trust Division bought a new position in shares of Astrana Health in the third quarter valued at $160,000. SG Americas Securities LLC acquired a new stake in shares of Astrana Health during the third quarter worth $680,000. Granite Bay Wealth Management LLC purchased a new stake in shares of Astrana Health during the third quarter valued at $290,000. Handelsbanken Fonder AB acquired a new position in shares of Astrana Health in the 3rd quarter valued at $492,000. Finally, GAMMA Investing LLC purchased a new position in Astrana Health in the 3rd quarter worth about $34,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.